Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jayne Donovan

Spinal Cord Injury Medicine Charleston, SC Medical Doctor

NPI 1407172794 CMS profile 1321487

316 Calhoun St, Charleston, SC 29401

Open in the dashboard

General payments

$199

13 records reported · program years 2019–2022

Research payments

$139

Paid to them · 1 record reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jayne Donovan of Charleston, SC is reported in the CMS Open Payments database as having received $199 across 13 general payments and $139 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Spinal Cord Injury Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $20 1
2020 General $23 2
2019 General $155 10
2019 Research $139 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jayne Donovan
  • Spinal Cord Injury Medicine median
  • Middle half of Spinal Cord Injury Medicine
  • National median

In program year 2025, general payments to Jayne Donovan were reported at $0. Among 53 Spinal Cord Injury Medicine profiles paid that year, the median was $118 and the middle half received between $45 and $354.

Show as a table
Year Jayne Donovan Spinal Cord Injury Medicine median Middle half National median
2019 $155 $117 $38–$194 $163
2020 $23 $111 $30–$321 $114
2021 $0 $146 $33–$514 $132
2022 $20 $115 $30–$450 $149
2023 $0 $139 $59–$436 $160
2024 $0 $122 $35–$350 $164
2025 $0 $118 $45–$354 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Merz North America, Inc. $57 3 payments
  2. Abbott Laboratories $20 1 payment
  3. C. R. Bard, Inc. & Subsidiaries $20 1 payment
  4. Ultragenyx Pharmaceutical Inc. $14 1 payment
  5. TerSera Therapeutics LLC $14 1 payment
  6. Flexion Therapeutics, Inc. $13 1 payment
  7. Scilex Pharmaceuticals Inc. $13 1 payment
  8. Collegium Pharmaceutical, Inc. $12 1 payment
  9. Avanir Pharmaceuticals, Inc. $12 1 payment
  10. Vertical Pharmaceuticals, LLC $11 1 payment
  11. Other $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $199 13 payments
Products named General payments · program years 2019–2022
  1. Xeomin $57 3 payments
  2. Proclaim Family of SCS IPGs $20 1 payment
  3. Crysvita $14 1 payment
  4. QMIIZ ODT $14 1 payment
  5. Zilretta $13 1 payment
  6. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $13 1 payment
  7. XTAMPZA $12 1 payment
  8. NUEDEXTA $12 1 payment
  9. XARELTO $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2022
  1. Merz North America, Inc. $139 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

250

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$14,759

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

9.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $12,061
Naloxone Hcl Generic 23 $1,362
Pantoprazole Sodium Generic 34 $240
Gabapentin Generic 23 $226
Atorvastatin Calcium Generic 27 $184
Levothyroxine Sodium Generic 20 $153
Tamsulosin Hcl Generic 18 $141
Famotidine Generic 13 $128
Rosuvastatin Calcium Generic 11 $118
Oxycodone Hcl Generic 20 $72

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$105,793

Medicare's payments for the services billed

Medicare patients

272

Average age 78

Services billed

1,574

151 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Atrial fibrillation 42%
Depression 41%
Diabetes 40%
Ischemic heart disease 40%
Chronic kidney disease 40%
Heart failure 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Spinal Cord Injury Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record